Daniel Flora: Promising data emerging from the BLUE-C colon cancer screening trial
Robin Zon, Director of Breast Oncology at Cincinnati Cancer Advisors, shared the following post by Daniel Flora, Medical Director of Oncology Research at St. Elizabeth Healthcare, on LinkedIn, adding the following:
“This is awesome – as medical oncologist appreciate many of our survivors are getting second and third and fourth cancers. Therefore, early detection and screening is imperative for these patients. And doing it safely and easily is also very important. Thank you for sharing this.”
Quoting Daniel Flora’s post:
“Promising data emerging from the BLUE-C colon cancer screening trial. Next-generation mt-sDNA test demonstrates even higher sensitivity for colorectal cancer screening (94%) and high-grade dysplasia (75%), compared with the current Cologuard test. St Elizabeth was a participating site in this pivotal study.”
For details click here.
Source: Robin Zon/LinkedIn and Daniel Flora/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023